Srt Fabry Galafold denied as non-formulary by Aetna?

Aetna's specific coverage criteria for srt fabry galafold are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Galafold as Non-Formulary

Aetna's commercial formularies tier specialty drugs, and Galafold — as a high-cost oral therapy for a rare disease — may be placed on a non-preferred specialty tier or excluded from certain plan formularies altogether. A non-formulary denial does not mean the drug is clinically inappropriate; it means the plan's benefit structure requires an additional authorization step before coverage is extended.

For ultra-rare conditions like Fabry disease, non-formulary status is frequently overturned through the formulary exception process, especially when no formulary alternative treats the same indication in the same patient.

## Your Federal Appeal Rights

Under ACA §2719, non-grandfathered plans must offer internal appeal followed by independent external review. The external review right is particularly powerful here because the external reviewer must assess whether the denial is consistent with the terms of the plan and applicable law — not just whether the drug appears on the formulary list. File your internal appeal first; if denied, immediately escalate to external review. The external review window is typically around four months from the initial denial. Expedited review is available if your medical situation is urgent.

## Formulary Exception: The Key Pathway

Most Aetna plans allow a formulary exception when: - No formulary alternative is medically appropriate for the specific patient. - The patient has a contraindication, intolerance, or clinical failure with a formulary alternative (document this with dates and clinical notes). - The requested drug is the only FDA-approved therapy for a specific indication or patient subpopulation.

For Fabry disease patients with an amenable mutation, Galafold and intravenous enzyme replacement therapies are not interchangeable for all patients. Your prescriber should explain in writing why the formulary alternatives are not appropriate for this individual.

## Documentation to Include

• Formulary alternative review: A written statement from the prescriber that addresses each formulary alternative by name, explaining the clinical reason each is not appropriate.
• Amenability documentation: Genetic report confirming the GLA mutation and its amenability status per the FDA-approved label — this establishes that Galafold is the only approved oral option.
• Clinical records: Chart notes showing disease stage, organ involvement, and treatment history.
• Prescriber letter: Should explicitly request a formulary exception and reference that no clinically equivalent formulary drug exists for this patient's mutation profile.

Attach Aetna's published formulary exception criteria alongside your prescriber's letter and answer each criterion point by point to give the reviewer everything needed to approve without further follow-up.